The landscape of weight loss medication has changed drastically in the past few years, with GLP-1 agonists rising to prominence as an effective tool for many struggling with obesity and related metabolic conditions.
Yet, despite their widespread use, questions linger around why some individuals experience dramatic results while others see only modest changes.
A recent study, unveiled at ENDO 2026, the Endocrine Society’s annual gathering in Chicago, promises to shed new light on this puzzle. This research, hailed as one of the largest real-world examinations of GLP-1 medication outcomes, specifically tirzepatide (commercially known as Mounjaro and Zepbound), offers fresh insights into the predictors of successful weight loss.
More than 80,000 adults participated in this ambitious study, which spanned from early 2024 through late 2025. Conducted collaboratively between Voy (Menwell Ltd.), a digital health company in London, and the Predictive Medicine Group at Boston Children’s Hospital and Harvard Medical School, the investigation aimed to decipher the reasons behind the variation in weight loss among users of tirzepatide.
The findings are striking. Women, those without pre-existing conditions like type 2 diabetes or hypertension, and individuals who actively engaged in behavioural strategies such as setting personal weight goals, were far more likely to achieve substantial weight loss.
Experts involved in the research utilised advanced statistical methods to unpick the data. Cox proportional hazards models helped them estimate the time it takes for someone to lose 20% of their total body weight. Meanwhile, multivariate mixed models revealed how demographic, clinical, and behavioural variables shaped weight loss trajectories over a twelve-month period. These tools allowed for a nuanced understanding of who benefits most from tirzepatide and under what circumstances.
The headline findings are clear. Women tended to lose more weight than men when using tirzepatide. Those with pre-existing conditions—type 2 diabetes, high cholesterol, hypertension, metabolic liver disease, or obstructive sleep apnoea—lost less weight on average.
Behavioural factors stood out as powerful predictors. Participants who had previously set weight goals or attempted structured diets saw better outcomes. Individuals lacking self-motivation struggled to lose weight even with medication.
Such revelations have immediate relevance for medical professionals and patients alike. Understanding that women respond differently compared to men, or that comorbidities dampen weight loss outcomes, can help doctors personalise treatment and set realistic expectations. It’s not just about prescribing a pill; it’s about crafting a holistic plan that factors in behavioural readiness and clinical background.
The study’s size and scope are noteworthy. With over 80,000 participants drawn from diverse backgrounds, it represents one of the largest real-world analyses of tirzepatide’s effectiveness. Unlike smaller or more narrowly focused clinical trials, this research captures the variability seen in everyday practice. The breadth of data provides confidence in the robustness of the findings.
Behavioural modification emerged as a central theme. Medical journals and institutions have long debated how best to integrate behavioural strategies with medication. This study reinforces the argument that drugs alone are not enough; behavioural interventions remain essential.
Doctors may need to spend more time helping patients set realistic goals, offering support for motivation, or referring them to structured programmes. The findings suggest that even the most advanced medications cannot replace the value of patient engagement.
For patients with pre-existing metabolic conditions, the news is less encouraging. Individuals with type 2 diabetes, hypertension, or metabolic liver disease lost less weight compared to those without these conditions. The reasons for this are not fully understood but may relate to underlying metabolic resistance or altered drug response. Nevertheless, even modest weight loss can be clinically meaningful for these groups.
Gender differences also warrant attention. Women consistently experienced greater weight reduction than men on tirzepatide. This could reflect differences in hormone regulation, fat distribution, or other physiological factors. From a clinical perspective, it suggests that sex should be considered when counselling patients about expected outcomes.
The practical implications are significant. Physicians can use these predictors to tailor their approach. For example, before starting tirzepatide, a doctor might assess a patient’s motivation level or history of previous dieting efforts. Those found to have motivational barriers could be offered additional behavioural support alongside medication. Setting clear expectations and emphasising the importance of personal goal-setting may foster better results.
This approach marks a shift away from one-size-fits-all medicine. Individualisation, matching the right intervention to the right person is becoming the gold standard in obesity management. It’s not just about handing over a prescription; it’s about recognising each patient’s unique circumstances and supporting them accordingly.
For health systems grappling with rising rates of obesity and associated diseases, these findings are timely. GLP-1 drugs like tirzepatide are expensive and not universally accessible. Knowing which patients are most likely to benefit can help optimise resources and improve outcomes.
Further studies are expected to build on these findings. The hope is that future work will continue to refine how treatments are delivered and monitored.
As health care continues to evolve towards precision medicine, studies like this remind us that behaviour matters as much as biology.
The combination of advanced drugs with tailored behavioural support represents the future of obesity management—a future where each patient’s journey is respected and supported according to their unique needs.
The post Study Finds Weight-Loss Success on GLP-1 Tirzepatide May Depend on Gender, Health History and Motivation first appeared on PP Health Malaysia.
